Mining and analysis of adverse drug event signals of cinacalcet and etelcalcetide

WANG Hongli; ZHONG Guizun; LI Dongxuan; SHEN Zhengze

doi:10.6039/j.issn.1001-0408.2024.08.15

您当前的位置：

首页 >

文章列表页 >

Mining and analysis of adverse drug event signals of cinacalcet and etelcalcetide

更新时间：2025-09-25

- Mining and analysis of adverse drug event signals of cinacalcet and etelcalcetide
- ZHONGGUO YAOFANG Vol. 35, Issue 8, Pages: 986-990(2024)
- 作者机构：
  
  1.重庆医科大学附属永川医院药学部，重庆　402100
  2.重庆医科大学附属第三医院药剂科，重庆　401100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.08.15
  CLC： R969.3
- Received：24 November 2023，
  
  Revised：2024-03-14，
  
  Accepted：22 March 2024，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
王红力,钟贵遵,李东炫,等.西那卡塞和依特卡肽不良事件信号的挖掘与分析[J].中国药房,2024,35(08):986-990.

WANG Hongli,ZHONG Guizun,LI Dongxuan,et al.Mining and analysis of adverse drug event signals of cinacalcet and etelcalcetide[J].ZHONGGUO YAOFANG,2024,35(08):986-990.
王红力,钟贵遵,李东炫,等.西那卡塞和依特卡肽不良事件信号的挖掘与分析[J].中国药房,2024,35(08):986-990. DOI： 10.6039/j.issn.1001-0408.2024.08.15.

WANG Hongli,ZHONG Guizun,LI Dongxuan,et al.Mining and analysis of adverse drug event signals of cinacalcet and etelcalcetide[J].ZHONGGUO YAOFANG,2024,35(08):986-990. DOI： 10.6039/j.issn.1001-0408.2024.08.15.

摘要

目的

挖掘并分析西那卡塞和依特卡肽的不良事件（ADE）信号，为临床安全用药提供参考。

方法

利用OpenVigil在线工具，收集美国FDA不良事件报告系统数据库2004年1月1日至2023年6月30日的西那卡塞和依特卡肽相关ADE报告，采用贝叶斯置信区间递进神经网络法对重点系统的ADE信号进行检测，并根据《国际医学用语词典》（26.0版）ADE术语集中的首选术语进行编码。

结果

分别检索到西那卡塞、依特卡肽ADE报告41 709、1 710份，重点系统阳性信号29、45个，未被药品说明书收录的阳性信号20、36个。低钙血症/血钙降低、血清甲状旁腺素（PTH）异常/血清PTH升高或降低是两药常见的ADE，均被检出；在未被药品说明书收录的信号中，检出了西那卡塞致钙化防御（代谢及营养类疾病）、骨饥饿综合征和高转换型骨病（肌肉骨骼及结缔组织类疾病）等新的中强、强信号，以及依特卡肽致猝死、坏死及治疗无反应（全身及给药部位反应），不稳定型心绞痛、心肌缺血（心脏器官疾病），肠穿孔、胃窦血管扩张、胃溃疡（胃肠道疾病）等新的中强、强信号。

结论

临床应用两药时，除需关注低钙血症、血清PTH异常等常见ADE外，还应监测一些新的潜在的ADE信号，如西那卡塞致骨饥饿综合征、钙化防御、心室疾病等，依特卡肽致猝死、心肌缺血、不稳定型心绞痛、肠穿孔及胃溃疡等；当出现新的ADE时，临床应及时评估患者的治疗获益与风险，更新治疗方案和药学监护计划，以保障患者用药安全。

Abstract

OBJECTIVE

To explore and analyze the adverse drug event （ADE） signals of cinacalcet and etelcalcetide， to provide a reference for safe drug use in the clinic.

METHODS

ADE reports related to cinacalcet and etelcalcetide were extracted from the FDA Adverse Event Reporting System from January 1st， 2004 to June 30th， 2023 using the OpenVigil online tool. The Bayesian confidence propagation neural network method was adopted to detect the signals of ADE from the key organ systems. The signals were encoded according to the preferred term in the ADE terminology set of the

Medical Dictionary for Regulatory Activities

（26.0 edition）.

RESULTS

A total 41 709 and 1 710 ADE reports were extracted， and 29 and 45 safety signals were detected in key systems for cinacalcet and etelcalcetide， respectively； 20 and 36 positive signals were not included in the drug instructions. Hypocalcemia/decreased serum calcium， abnormal blood parathyroid hormone （PTH）/increased or decreased serum PTH were common ADEs of the two drugs， which were detected in the study. Among the signals not included in the drug instructions， new moderate and strong signals were detected， such as cinacalcet-induced calcification defense （metabolic and nutritional diseases）， bone starvation syndrome and high conversion bone diseases （musculoskeletal and connective tissue diseases） as well as etelcalcetide-induced sudden death， necrosis and treatment of non-responders （general disorders， administration site）， unstable angina pectoris， myocardial ischemia （cardiac diseases）， intestinal perforation， gastric antrum vasodilation and gastric ulcer （gastrointestinal diseases）.

CONCLUSIONS

In the clinical application of the two drugs， apart from the common ADEs such as hypocalcemia and abnormal blood PTH， the surveillance of some new potential ADEs should also be carried out， such as bone starvation syndrome， calcification defense， ventricular disease and other cinacalcet-induced ADEs， sudden death， myocardial ischemia， unstable angina pectoris， intestinal perforation， gastric ulcer and other etecalcetide-induced ADEs. If new ADEs appear， clinic should promptly assess the benefits and risks， and update the treatment plan and pharmacological monitoring plan to ensure the safety of patient medication.

关键词

Keywords

references

贺西南，石宏斌 . 慢性肾脏病继发性甲状旁腺功能亢进的研究进展 [J ] . 中国中西医结合肾病杂志， 2019 ， 20 （ 5 ）： 456 - 459 .

HE X N ， SHI H B . Research progress of secondary hyperparathyroidism in chronic kidney disease [J ] . Chin J Integr Tradit West Nephrol ， 2019 ， 20 （ 5 ）： 456 - 459 .

FRANKLYN J A ， SHEPPARD M C ， MAISONNEUVE P . Thyroid function and mortality in patients treated for hyperthyroidism [J ] . JAMA ， 2005 ， 294 （ 1 ）： 71 - 80 .

国家肾脏疾病临床医学研究中心 . 中国慢性肾脏病矿物质和骨异常诊治指南概要 [J ] . 肾脏病与透析肾移植杂志， 2019 ， 28 （ 1 ）： 52 - 57 .

National Clinical Research Center of Kidney Diseases . Summary of China 2018 chronic kidney disease-mineral and bone disorder guideline [J ] . Chin J Nephrol Dial Transplant ， 2019 ， 28 （ 1 ）： 52 - 57 .

EVANS M ， METHVEN S ， GASPARINI A ， et al . Cinacalcet use and the risk of cardiovascular events，fractures and mortality in chronic kidney disease patients with secon-dary hyperparathyroidism [J ] . Sci Rep ， 2018 ， 8 （ 1 ）： 2103 .

MOROSETTI M ， JANKOVIC L ， ZAPPALÀ L ， et al . Long-term use of etelcalcetide for the treatment of secon-dary hyperparathyroidism in patients undergoing hemo-dialysis for end-stage renal failure：a real-life retrospective observational study [J ] . Int Urol Nephrol ， 2023 ， 55 （ 7 ）： 1865 - 1873 .

YOKOYAMA K ， FUKAGAWA M ， SHIGEMATSU T ， et al . Safety and efficacy of etelcalcetide，an intravenous calcimimetic，for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism：results of a post-marketing surveillance in Japan [J ] . Clin Exp Nephrol ， 2021 ， 25 （ 1 ）： 66 - 79 .

PALMER S C ， MAVRIDIS D ， JOHNSON D W ， et al . Comparative effectiveness of calcimimetic agents for secon-dary hyperparathyroidism in adults：a systematic review and network meta-analysis [J ] . Am J Kidney Dis ， 2020 ， 76 （ 3 ）： 321 - 330 .

NOGUCHI Y ， NAGASAWA H ， TACHI T ， et al . Signal detection of oral drug-induced dementia in chronic kidney disease patients using association rule mining and Bayesian confidence propagation neural network [J ] . Pharmazie ， 2019 ， 74 （ 9 ）： 570 - 574 .

张妮，王红力，钟贵遵，等 . 基于BCPNN法对培门冬酶和左旋门冬酰胺酶上市后安全警戒信号的挖掘与评价 [J ] . 中国药房， 2021 ， 32 （ 16 ）： 2012 - 2018 .

ZHANG N ， WANG H L ， ZHONG G Z ， et al . Mining and evaluation of post-marketing safe alert signals of pegaspargase and L-asparaginase based on BCPNN method [J ] . China Pharm ， 2021 ， 32 （ 16 ）： 2012 - 2018 .

陈文戈，李婵娟，江静，等 . 基于BCPNN法的药品不良反应信号检测与自动预警技术研究 [J ] . 计算机应用研究， 2009 ， 26 （ 4 ）： 1394 - 1397 .

CHEN W G ， LI C J ， JIANG J ， et al . Research of signal detection and automatic warning technology for adverse drug reaction based on BCPNN method [J ] . Appl Res Comput ， 2009 ， 26 （ 4 ）： 1394 - 1397 .

VAHE C ， BENOMAR K ， ESPIARD S ， et al . Diseases associated with calcium-sensing receptor [J ] . Orphanet J Rare Dis ， 2017 ， 12 （ 1 ）： 19 .

EIDMAN K E ， WETMORE J B . Managing hyperparathyroidism in hemodialysis：role of etelcalcetide [J ] . Int J Nephrol Renovasc Dis ， 2018 ， 11 ： 69 - 80 .

ROZENTRYT P ， NIEDZIELA J T ， HUDZIK B ， et al . Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy [J ] . Pol Arch Med Wewn ， 2015 ， 125 （ 1/2 ）： 54 - 64 .

WARADY B A ， NG E ， BLOSS L ， et al . Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis [J ] . Pediatr Nephrol ， 2020 ， 35 （ 9 ）： 1679 - 1697 .

KARABOYAS A ， MUENZ D ， HWANG Y ， et al . Etelcalcetide versus cinacalcet in hemodialysis patients in the United States：a facility calcimimetic approach to assess real-world effectiveness [J ] . Kidney Med ， 2022 ， 4 （ 6 ）： 100475 .

WU W D ， ZHOU H R ， PESTKA J J . Potential roles for calcium-sensing receptor（CaSR）and transient receptor potential ankyrin-1（TRPA1）in murine anorectic response to deoxynivalenol（vomitoxin） [J ] . Arch Toxicol ， 2017 ， 91 （ 1 ）： 495 - 507 .

DUFNER M M ， KIRCHHOFF P ， REMY C ， et al . The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands [J ] . Am J Physiol Gastrointest Liver Physiol ， 2005 ， 289 （ 6 ）： G1084 - G1090 .

GOSWAMI S . Interplay of potassium channel，gastric parietal cell and proton pump in gastrointestinal physiology，pathology and pharmacology [J ] . Minerva Gastroenterol ， 2022 ， 68 （ 3 ）： 289 - 305 .

YOUSAF F ， CHARYTAN C . Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism [J ] . Ren Fail ， 2014 ， 36 （ 1 ）： 131 - 138 .

KOUBAR S H ， QANNUS A A ， MEDAWAR W ， et al . Hungry bone syndrome two weeks after starting cinacalcet：a call for caution [J ] . CEN Case Rep ， 2018 ， 7 （ 1 ）： 21 - 23 .

KAMPSCHREUR L M ， HOOGEVEEN E K ， OP DEN AKKER J W ， et al . A haemodialysis patient with back pain：brown tumour as a cause of spinal cord compression under cinacalcet therapy [J ] . NDT Plus ， 2010 ， 3 （ 3 ）： 291 - 295 .

EIDMAN K E ， WETMORE J B . Treatment of secondary hyperparathyroidism：how do cinacalcet and etelcalcetide differ？ [J ] . Semin Dial ， 2018 ， 31 （ 5 ）： 440 - 444 .

DANESE M D ， LUBECK D ， BELOZEROFF V ， et al . Real world use and effects of calcimimetics in treating mineral and bone disorder in hemodialysis patients [J ] . Am J Nephrol ， 2020 ， 51 （ 10 ）： 815 - 822 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Data mining of severe cutaneous adverse reactions related to immune checkpoint inhibitors in the FAERS

Detection and evaluation of the signals of amlodipine and lercanidipine based on FAERS database

西那卡塞治疗继发性甲状旁腺功能亢进症的研究进展

Related Author

HUANG Mengwen

PU Shiyun

WANG Lichen

TANG Mengjiao

LONG Xia

ZHOU Houfeng

ZHONG Guizun

ZHANG Ni

Related Institution

Dept. of Pharmacy， Chengdu Fifth People’s Hospital

School of Pharmacy， Chengdu University of Traditional Chinese Medicine

School of Pharmacy，North Sichuan Medical College， Sichuan Nanchong

School of Pharmacy， Southwest Medical University

School of Pharmacy， Chongqing Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰